This trial will test a new combination of drugs to treat patients with MDS who have not responded to other treatments.
- Myelodysplastic Syndrome, High Grade
2 Primary · 4 Secondary · Reporting Duration: Study start date to study end date, or death, whichever comes first, up to 4 years.
2 Treatment Groups
1 of 2
1 of 2
51 Total Participants · 2 Treatment Groups
Primary Treatment: Omacetaxine · No Placebo Group · Phase 1 & 2
Who is running the clinical trial?
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
For what purpose is Azacitidine typically prescribed?
"Azacitidine can be used as an effective treatment for induction chemotherapy, refractory anemias, and leukemia, myelocytic, acute." - Anonymous Online Contributor
What are the investigators hoping to learn from this research?
"The main objective of this trial is to monitor the Overall Response Rate over a period of four years. Secondary objectives include Progression Free Survival, Duration of Response, and Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability])." - Anonymous Online Contributor
Can new patients still sign up for this research project?
"Yes, as of today this trial is still recruiting patients. The original posting was on September 17th, 2018 with the latest update being October 19th, 2021." - Anonymous Online Contributor
Do we have any prior data to draw upon regarding Azacitidine?
"There are currently 183 ongoing clinical trials investigating the use of azacitidine, 33 of which are in Phase 3. While several trials for azacitidine are located in Houston, Texas, there are a total of 5735 locations worldwide where clinical trials for azacitidine are taking place." - Anonymous Online Contributor